Redline Comparison of Michniak-Kohn Declarations in IPR2018-00608 and IPR2019-00207 Redline Comparison of Gilmore Declarations in IPR2018-00608 and IPR2019-00207 Petitioner’s Notice of Paragraph IV Certification to Patent Owner (February 22, 2019) (truncated) Declaration of Elizabeth B. Hagan in Support of Patent Owner Almirall, LLC’s Motion for Admission Pro Hac Vice International Patent Application Publication No. WO 2011/014627 (“Ahluwalia”) Dina Anderson, Finding a Place for Topical Anti-inflammatory Acne Therapy, Practical Dermatology 17 (July 2009) (“Anderson”) Christin N. Collier et al., The prevalence of acne in adults 20 years and older, 58 J. Am. Acad. Dermtol.

133 (2011) (“Fabbrocini”) Zoe D. Draelos et al., Two randomized studies demonstrate the efficacy and safety of dapsone gel, 5% for the treatment of acne vulgaris, 46 J. Am. Acad. Dermatol.

783 (2011) (“Tanghetti”) Diane Thiboutot et al., An aqueous gel fixed combination of clindamycin phosphate 1.2% and benzoyl peroxide 2.5% for the once-daily treatment of moderate to severe acne vulgaris: Assessment of efficacy and safety in 2813 patients, 59 J. Am. Acad. Dermatol.

Exhibit No. 2060 2061 2062 2063 2064 2065 2066 2067 2068 2069 2070 Description M. P. Heffernan et al., A Pilot Study of the Safety and Efficacy of Picolinic Acid Gel in the Treatment of Acne Vulgaris, 156 British J. Dermatol.

548 (2006) (“Heffernan”) Janusz Marcinkiewicz et al., Topical Taurine Bromamine, a New Candidate in the Treatment of Moderate Inflammatory Acne Vulgaris - A Pilot Study, 18 Eur.

133 (2011) (“Fabbrocini”) Zoe D. Draelos et al., Two randomized studies demonstrate the efficacy and safety of dapsone gel, 5% for the treatment of acne vulgaris, 46 J. Am. Acad. Dermatol.

783 (2011) (“Tanghetti”) Diane Thiboutot et al., An aqueous gel fixed combination of clindamycin phosphate 1.2% and benzoyl peroxide 2.5% for the once-daily treatment of moderate to severe acne vulgaris: Assessment of efficacy and safety in 2813 patients, 59 J. Am. Acad. Dermatol.

Exhibit No. 2060 Description M. P. Heffernan et al., A Pilot Study of the Safety and Efficacy of Picolinic Acid Gel in the Treatment of Acne Vulgaris, 156 British J. Dermatol.

548 (2006) (“Heffernan”) Janusz Marcinkiewicz et al., Topical Taurine Bromamine, a New Candidate in the Treatment of Moderate Inflammatory Acne Vulgaris - A Pilot Study, 18 Eur.

41 (2012) (“Chang”) Supplemental Declaration of David W. Osborne, Ph.D. (served August 30, 2019) Erick H. Turner, How to access and process FDA drug approval packages for use in research, BMJ (2013) ("Turner 2013") (served August 30, 2019) Manual of Policies and Procedures - Center for Drug Evaluation and Research (served August 30, 2019) Transcript of Deposition of Bozena B. Michniak-Kohn, Ph.D., FAAPS, M.R.Pharm.S., dated December 6, 2019 Transcript of Deposition of Elaine S. Gilmore, M.D., Ph.D., dated December 12, 2019 Transcript of PTAB Conference Call, dated January 17, 2020 2061 2062 2063 2064 2065 2066 2067 2068 2069 2070

Amneal Exhibit # 1019 1020 1021 1022 1023 1024 1025 1026 1027 1028 1029 1030 1031 1032 1033 Description Curriculum Vitae for Elaine S. Gilmore, M.D., Ph.D. Affidavit of Christopher Butler Intentionally left blank Wozel, D., “Innovative Use of Dapsone” Dermatol.

46: 697- 712 (2007) (“Thiboutot”) Nguyen, R. and Su, J., “Treatment of Acne Vulgaris” Pediatrics and Child Health 21: 119-125 (2010) (“Nguyen”) Williams, H., et al., “Acne vulgaris” Lancet 379: 361–72 (2012) (“Williams”) Sepineo™ P 600 Brochure Barclay, L., “Use of Topical Corticosteroids for Dermatologic Conditions Reviewed” Medscape - Jan 21, 2009, accessed from https://www.medscape.com/viewarticle/587159_print (“Barclay”) Remington: The Science and Practice of Pharmacy, 21st Ed., Lippincott Williams & Wilkins: Baltimore, MD (2005) (“Remington”) Kim, J-Y., et al., “Rheological properties and microstructures of Carbopol gel network system,” Colloid.

Male Patients With Facial Acne Vulgaris: Gender as a Clinically Relevant Outcome Variable,” Journal of Drugs in Dermatology 11:1417-1421 (2012) Intentionally left blank Neutralizing Carbopol® and Pemulen® Polymers in Aqueous and Hydroalcoholic Systems, published January 2002 (“Noveon Technical Data Sheet”) 2010 Inactive Ingredient Database, available at: http://wayback.archive-it.org/7993/20170112022245/http:/www.fda.

Sullivan, D., et al., “A review of the nonclinical safety of Transcutol®, a highly purified form of diethylene glycol monoethyl ether (DEGEE) used as a pharmaceutical excipient,” Food and Chemical Toxicology 72: 4-50 (2014) FDA Inactive Ingredient Database Field Descriptions Andersson, D., “Evonik-Degussa expands its cooperation with Alsiano,” Pharma & Healthcare News 7:1-10 (2007) File History of U.S. Patent No. 9,161,926 Deposition Transcript for Julie C. Harper, M.D., Case IPR2018- 00608 (March 11, 2019) 1045 1046 1047 1048 1049 1050 1051 1052 1053 1054 1055 1056 1057 Case IPR2019-00207 Patent 9,517,219 B2

Amneal Exhibit # Description 1079 Emails dated from December 31, 2019 to January 23, 2020 between James Trainor, Adam LaRock, Elizabeth Hagan, RJ Shea, Dennies Varughese, and Tyler Liu regarding the confidentiality of Dr. Warner’s deposition transcript [REDACTED] Deposition Transcript of Kevin Warner, Allergan, Inc. v. Taro Pharmaceutical Industries Ltd., and Taro Pharmaceuticals Inc., Civil Action No. 17-663 (D.Del. July 18, 2018) 10252301_1.docx 1080